TY - JOUR
T1 - Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction.
AU - Ardissino, Diego
AU - Berzuini, Carlo
AU - Merlini, Piera Angelica
AU - Mannuccio Mannucci, Pier
AU - Surti, Aarti
AU - Burtt, Noel
AU - Voight, Benjamin
AU - Tubaro, Marco
AU - Peyvandi, Flora
AU - Spreafico, Marta
AU - Celli, Patrizia
AU - Lina, Daniela
AU - Notarangelo, Maria Francesca
AU - Ferrario, Maurizio
AU - Fetiveau, Raffaela
AU - Casari, Giorgio
AU - Galli, Michele
AU - Ribichini, Flavio
AU - Rossi, Marco L.
AU - Bernardi, Francesco
AU - Marziliano, Nicola
AU - Zonzin, Pietro
AU - Mauri, Francesco
AU - Piazza, Alberto
AU - Foco, Luisa
AU - Bernardinelli, Luisa
AU - Altshuler, David
AU - Kathiresan, Sekar
AU - Italian Atherosclerosis, Thrombosis, [Unknown]
PY - 2011/7/19
Y1 - 2011/7/19
N2 - The purpose of this study was to test whether the 9p21.3 variant rs1333040 influences the occurrence of new cardiovascular events and coronary atherosclerosis progression after early-onset myocardial infarction. 9p21.3 genetic variants are associated with ischemic heart disease, but it is not known whether they influence prognosis after an acute coronary event. Within the Italian Genetic Study of Early-onset Myocardial Infarction, we genotyped rs1333040 in 1,508 patients hospitalized for a first myocardial infarction before the age of 45 years who underwent coronary angiography without index event coronary revascularization. They were followed up for major cardiovascular events and angiographic coronary atherosclerosis progression. Over 16,599 person-years, there were 683 cardiovascular events and 492 primary endpoints: 77 cardiovascular deaths, 223 reoccurrences of myocardial infarction, and 383 coronary artery revascularizations. The rs1333040 genotype had a significant influence (p = 0.01) on the primary endpoint, with an adjusted hazard ratio of 1.19 (95% confidence interval [CI]: 1.08 to 1.37) for heterozygous carriers and 1.41 (95% CI: 1.06 to 1.87) for homozygous carriers. Analysis of the individual components of the primary endpoints provided no significant evidence that the rs1333040 genotype influenced the hazard of cardiovascular death (p = 0.24) or the reoccurrence of myocardial infarction (p = 0.57), but did provide significant evidence that it influenced on the hazard of coronary revascularization, with adjusted heterozygous and homozygous ratios of 1.38 (95% CI: 1.17 to 1.63) and 1.90 (95% CI: 1.36 to 2.65) (p = 0.00015), respectively. It also significantly influenced the angiographic endpoint of coronary atherosclerosis progression (p = 0.002). In early-onset myocardial infarction, the 9p21.3 variant rs1333040 affects the progression of coronary atherosclerosis and the probability of coronary artery revascularization during long-term follow-up. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
AB - The purpose of this study was to test whether the 9p21.3 variant rs1333040 influences the occurrence of new cardiovascular events and coronary atherosclerosis progression after early-onset myocardial infarction. 9p21.3 genetic variants are associated with ischemic heart disease, but it is not known whether they influence prognosis after an acute coronary event. Within the Italian Genetic Study of Early-onset Myocardial Infarction, we genotyped rs1333040 in 1,508 patients hospitalized for a first myocardial infarction before the age of 45 years who underwent coronary angiography without index event coronary revascularization. They were followed up for major cardiovascular events and angiographic coronary atherosclerosis progression. Over 16,599 person-years, there were 683 cardiovascular events and 492 primary endpoints: 77 cardiovascular deaths, 223 reoccurrences of myocardial infarction, and 383 coronary artery revascularizations. The rs1333040 genotype had a significant influence (p = 0.01) on the primary endpoint, with an adjusted hazard ratio of 1.19 (95% confidence interval [CI]: 1.08 to 1.37) for heterozygous carriers and 1.41 (95% CI: 1.06 to 1.87) for homozygous carriers. Analysis of the individual components of the primary endpoints provided no significant evidence that the rs1333040 genotype influenced the hazard of cardiovascular death (p = 0.24) or the reoccurrence of myocardial infarction (p = 0.57), but did provide significant evidence that it influenced on the hazard of coronary revascularization, with adjusted heterozygous and homozygous ratios of 1.38 (95% CI: 1.17 to 1.63) and 1.90 (95% CI: 1.36 to 2.65) (p = 0.00015), respectively. It also significantly influenced the angiographic endpoint of coronary atherosclerosis progression (p = 0.002). In early-onset myocardial infarction, the 9p21.3 variant rs1333040 affects the progression of coronary atherosclerosis and the probability of coronary artery revascularization during long-term follow-up. Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
KW - Genetic Epidemiology
U2 - 10.1016/j.jacc.2010.11.075
DO - 10.1016/j.jacc.2010.11.075
M3 - Article
SN - 0735-1097
VL - 58
SP - 426
EP - 434
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 4
ER -
